Vimarsana
Biggest News Aggregation in the World

Page 4 - Axol Bioscience News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Axol Bioscience. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Axol Bioscience Today - Breaking & Trending Today

Using human iPSC-derived cells to revolutionize the field of neurodegenerative disease - Vimarsana News

Using human iPSC-derived cells to revolutionize the field of neurodegenerative disease

In this interview, we speak to Axol Bioscience about their human iPSC-derived cells and how they have the potential to revolutionize the field of neurodegenerative disease.

Induced Pluripotent Stem Cell (iPSC) Global Market Report 2022: Increased Prevalence of Chronic Disorders Driving 7.8% Annual Growth - Vimarsana News

Induced Pluripotent Stem Cell (iPSC) Global Market Report 2022: Increased Prevalence of Chronic Disorders Driving 7.8% Annual Growth

/PRNewswire/ -- The "Induced Pluripotent Stem Cell (iPSC) Global Market Report 2022, By Derived Cell Type, By Application, By End-User" report has been added...

Global Roundup: Denmark's Ascendis Sees "Real Control" in Hypothyroidism - Vimarsana News

Global Roundup: Denmark's Ascendis Sees "Real Control" in Hypothyroidism

At ENDO 2022, Ascendis will share Phase II and III data showing clinical efficacy for its investigational product candidate for hypoparathyroidism. For this and more, see inside.

Axol Bioscience introduces CiPA-validated human stem cell-derived ventricular cardiomyocytes to help improve drug discovery - Vimarsana News

Axol Bioscience introduces CiPA-validated human stem cell-derived ventricular cardiomyocytes to help improve drug discovery

Axol Bioscience Ltd. (Axol), an established provider of iPSC-derived cells, media, and characterization services for life science discovery, today announced that its human induced pluripotent stem cell (iPSC)-derived ventricular cardiomyocytes have undergone comprehensive in vitro pro-arrhythmia assay (CiPA) validation.

Axol Bioscience Introduces CiPA-Validated Human Stem Cell-Derived Ventricular Cardiomyocytes to Help Improve Drug Discovery - Vimarsana News

Axol Bioscience Introduces CiPA-Validated Human Stem Cell-Derived Ventricular Cardiomyocytes to Help Improve Drug Discovery

Comprehensive in vitro pro-arrhythmia assay used to validate Axol's cardiomyocytes for cardiac safety testing Axol Bioscience Ltd. (Axol), an established provider of iPSC-derived cells, media, and